Foundation

favorite Donate

person Sign In / Create Account

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

HealthTree Podcast for AML

Jul 14, 2022 / 11:00AM EDT

Listen to Podcast

Event Description

Name: Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital
Start: 2022-07-14T11:00:00-04:00
End: 2022-07-14T12:00:00-04:00

IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728

*You need to join by phone if you want to ask Dr. Shallis your questions.*

The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a poor prognosis, however, the research indicates progress is being made in this area.

Join us live on Thursday, July 14th at 11 am EST to hear from Dr. Rory Shallis with Yale New Haven Hospital who will be discussing the TP53 mutation in AML, current treatment options available, and the latest research and clinical trials using novel investigational agents to target this mutation. There will be time at the end of the show to ask Dr. Shallis your questions directly!

Thank you to our episode sponsor, Bristol Myers Squibb.

Schedule & Agenda

Welcome

11:00AM

Kerith Amen

Welcome, Announcements & Introduction

11:00AM

Kerith Amen

Welcome

Welcome, Announcements & Introduction

Interview

11:05AM

Dr. Rory Shallis

Dr. Shallis will discuss the TP53 mutation in AML and the current treatment options available, as well as clinical trials exploring the latest research and novel drugs.

11:05AM

Dr. Rory Shallis

Interview

Dr. Shallis will discuss the TP53 mutation in AML and the current treatment options available, as well as clinical trials exploring the latest research and novel drugs.

Q&A

11:50AM

Audience

Audience is able to call in to the radio show, (515) 602-9728, to ask Dr. Shallis questions about what was discussed during our interview today.

11:50AM

Audience

Q&A

Audience is able to call in to the radio show, (515) 602-9728, to ask Dr. Shallis questions about what was discussed during our interview today.

Speakers & Moderators

Kerith Amen

New Orleans, Louisiana

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.

Read Bio

Rory Shallis, MD

New Haven, CT

Dr. Shallis is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS. He is an author on more than 75 peer-reviewed publications and book chapters, most of which he was first author on. His work has been published in many prestigious journals.

Read Bio